Courtesy of Dr. Carlos Fava. Atrial fibrillation (AF) and fast heart rate (>70 lpm) have been shown to increase the risk of mitral valve repair surgery. The MitraClip has shown benefits in high risk patients, but its relation to abnormal heart rhythm has not yet been established. 760 patients were analyzed; 315 (52.4%) presented<a href="https://solaci.org/en/2017/03/06/mitraclip-impact-of-sinus-rhythm-and-heart-rate/" title="Read more" >...</a>
Neurological complications during transcatheter aortic valve replacement (TAVR) may be reduced with cerebral protection devices; this study was designed to explore that hypothesis. The study enrolled 363 patients undergoing TAVR in 19 sites and divided them in three arms: a safety arm (n = 123), a device imaging arm (n = 121), and a non-device imaging arm (n = 119). The<a href="https://solaci.org/en/2017/03/02/cerebral-protection-in-tavr-does-it-improve-cognitive-function/" title="Read more" >...</a>
Cerebral embolic protection is a strategy to prevent embolization of thrombotic or calcific debris during transcatheter aortic valve replacement (TAVR). A number of randomized and controlled studies have tested the safety and efficacy of various devices, though none of them have enough statistical power to show significant differences in end points. While preliminary<a href="https://solaci.org/en/2017/03/02/meta-analysis-on-cerebral-embolic-protection-in-tavr/" title="Read more" >...</a>
This work studies the natural history of aortic stenosis and the optimal timing to intervene elderly patients with asymptomatic severe aortic stenosis. This disease is increasingly misdiagnosed in the elderly population, and this goes hand in hand with enhanced therapeutic options. Prior studies on the natural history of this disease were made on<a href="https://solaci.org/en/2017/02/14/asymptomatic-severe-aortic-stenosis-in-the-elderly-when-to-intervene/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. Aortic valve calcification and mitral annular calcification have the same etiology and are frequently present in high-risk patients undergoing transcatheter aortic valve replacement (TAVR). The implications of mitral annular calcification for patients undergoing TAVR has not been entirely clarified yet. The study examined 782 patients with severe aortic stenosis who underwent<a href="https://solaci.org/en/2017/02/14/tavr-reasons-to-consider-mitral-annular-calcification/" title="Read more" >...</a>
Readmissions are frequent after cardiovascular procedures and they significantly increase healthcare costs. Data on readmission need within the first month after successful transcatheter aortic valve replacement (TAVR) are limited. The registry included all TAVR patients surviving index hospitalization between January and February 2013 for readmission incidence, predictors, causes and costs within 30 days. <a href="https://solaci.org/en/2017/01/28/4-readmission-predictors-after-successful-tavr/" title="Read more" >...</a>
Both surgical and medical treatment options for functional mitral regurgitation are limited. The Cardioband system (Valtech Cardio, OrYehuda, Israel) is a new transvenous, transseptal direct mitral annuloplasty device. This work studied the safety and efficacy of this new device 6 months after implantation. Thirty-one patients with moderate to severe mitral regurgitation associated with severe impairment of the left systolic ventricular<a href="https://solaci.org/en/2017/01/18/mitral-annuloplasty-with-a-cardioband-device-effective-in-functional-mitral-regurgitation/" title="Read more" >...</a>
There is little information on the short and mid-term evolution of cognitive function after transcatheter aortic valve replacement (TAVR). The aim of this study was to describe global changes in cognitive function and changes in specific cognitive domains one year after TAVR. Fifty one patients undergoing TAVR, median age 80, were prospectively followed<a href="https://solaci.org/en/2017/01/11/post-tavr-cognitive-function-at-short-term-better-or-worse/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. The prevalence of atrial fibrillation in patients undergoing transcatheter aortic valve replacement (TAVR) is high (32.9%, according to the PARTNER Trial, and 46.8%, according to the CoreValve High-Risk Study), and is associated with thromboembolic events (as in all other populations). Apixaban has shown to benefit patients with nonvalvular atrial fibrillation,<a href="https://solaci.org/en/2017/01/11/apixaban-an-alternative-for-patients-with-atrial-fibrillation-undergoing-tavr/" title="Read more" >...</a>
We thank all the speakers of the Chile 2016 Sessions who shared their presentations to contribute to our mission of promoting the dissemination of information from research and clinical practice in Interventional Cardiology. You can read and/or download them below Lluberas, Ricardo. “Role of pharmacovasive therapy in the treatment of IAMcEST. Implications for Latin<a href="https://solaci.org/en/2017/01/07/see-the-presentations-of-the-2016-chile-sessions/" title="Read more" >...</a>